This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Will Gritstone bio Inc. (GRTS) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Gritstone bio Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx (RARE) Begins Angelman Syndrome Study in Canada
by Zacks Equity Research
Ultragenyx (RARE) and GeneTx Biotherapeutics dose the first patient in a phase I/II study on GTX-102 for treating patients with Angelman syndrome in Canada.
Gritstone bio Inc. (GRTS) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Gritstone bio Inc. (GRTS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Gritstone (GRTS) Inks Deal With CEPI for Coronavirus Vaccine
by Zacks Equity Research
Gritstone (GRTS) signs an agreement with CEPI for up to $20.6 million to develop its COVID-19 vaccine program with an initial focus in South Africa. Shares rise.
Gritstone bio Inc. (GRTS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 37.74% and -5.23%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Gritstone bio Inc. (GRTS) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Gritstone bio Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gritstone Oncology, Inc. (GRTS) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of 121.74% and 1223.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Gritstone Oncology, Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of 0.00% and 12.33%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Gritstone Oncology, Inc. (GRTS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead (GILD) Tops Q4 Earnings & Sales on Strong Veklury Demand
by Zacks Equity Research
Gilead (GILD) reports better-than-expected results for the fourth quarter owing to increased Veklury sales as the coronavirus pandemic continues.
Moving Average Crossover Alert: Gritstone Oncology (GRTS)
by Zacks Equity Research
Gritstone Oncology (GRTS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Biotech Stock Roundup: ALXN Pauses Study, ACRS & GRTS Surge, & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Alexion (ALXN), Aclaris (ACRS) and Biohaven (BHVN).
Gritstone (GRTS) to Begin Coronavirus Vaccine Study, Stock Up
by Zacks Equity Research
Gritstone (GRTS) will develop a second generation vaccine candidate against COVID-19 with the potential for both prolonged protection and potency against spike mutants of the virus. Stock rises.
Gritstone Oncology, Inc. (GRTS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of 10.39% and -59.33%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Gritstone Oncology, Inc. (GRTS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gritstone Oncology (GRTS): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Gritstone Oncology (GRTS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Gritstone Oncology Inc (GRTS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gritstone Oncology Inc (GRTS) delivered earnings and revenue surprises of 14.46% and 5.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Gritstone Oncology, Inc. (GRTS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of -1.32% and -26.33%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Gritstone Oncology, Inc. (GRTS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of -13.24% and -18.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Gritstone Oncology, Inc. (GRTS) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.